Cytori Reports Q2 2018 Business and Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Cytori Reports Q2 2018 Business and Financial Results

Maxim Group Downgrades Cytori Therapeutics, Inc. (CYTX) to Hold

August 15, 2018 7:40 AM EDT

Maxim Group analyst Jason McCarthy downgraded Cytori Therapeutics, Inc. (NASDAQ: CYTX) from Buy to Hold and removes their price target.

McCarthy said their fundamental view around the company's key programs of 0918 (liposomal doxorubicin) and cell therapy (scleroderma, stress urinary incontinence) are unchanged, but... More

Cytori Therapeutics, Inc. (CYTX) PT Lowered to $5 at H.C. Wainwright on Rising Share Count

August 15, 2018 7:12 AM EDT

H.C. Wainwright analyst Jason Kolbert lowered the price target on Cytori Therapeutics, Inc. (NASDAQ: CYTX) to $5.00 (from $6.00) while maintaining a Buy rating.

Kolbert notes while catalysts lay ahead they are lowering the price target on a rising share... More

Cytori Therapeutics (CYTX) Misses Q2 EPS by 14c

August 14, 2018 4:23 PM EDT

Cytori Therapeutics (NASDAQ: CYTX) reported Q2 EPS of ($0.59), $0.14 worse than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.

... More